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A B S T R A C T
Background: Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with
sudden death, heart failure, and stroke. The aim of the present study was to evaluate the prevalence and
types of mutations in symptomatic patients with HCM in Taiwan.
Methods: Thirty-eight HCM index patients (mean age 60  16 years) underwent systematic mutation
screening of eight sarcomeric genes: b-myosin heavy chain (MYH7), myosin-binding protein C (MYBPC3),
troponin T (TNNT2), troponin I (TNNI3), myosin ventricular regulatory light chain 2 (MYL2), myosin
ventricular essential light chain 1 (MYL3), a-tropomyosin (TPM1), and cardiac a-actin (ACTC), using direct
DNA sequencing. In silico programs predicted damaging amino acids. In the positive families, genotype–
phenotype correlation studies were done.
Results: Overall, 13 mutations were identiﬁed in 13 index patients (34.2%). The three most frequently
mutated genes were MYH7, MYBPC3, and TNNT2. One patient carried double mutations. Five mutations
(MYH7 R147S; MYBPC3 R597Q; MYBPC3 W1007R; TNNI3 E124Q; MYL3 R63C) were novel; all were
missense mutations. Analysis using in silico tools showed near consensus to classify these ﬁve novel
mutations as pathological. Family pedigree analysis showed the presence of cosegregation in at least two
affected members in each proband family, but incomplete penetrance in young family members with a
positive genotype.
Conclusions: We identiﬁed 13 HCM pedigrees, including 5 carrying novel mutations and 1 with a double
mutation. The three most commonly mutated genes were MYH7, MYBPC3, and TNNT2. These results,
together with genetic counseling, could lead to earlier diagnosis and better management of family
members at risk of HCM.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM), clinically deﬁned as
thickening of the myocardial wall in the absence of any other
cause of left ventricular (LV) hypertrophy, is often inherited
genetically, and affects 1:500 individuals [1,2]. The clinical and
pathological manifestations are diverse and they range from
asymptomatic clinical courses to severe heart failure and sudden
cardiac death (SCD). It is caused by 11 or more genes encoding* Corresponding authors at: Division of Cardiology, Taipei Veterans General
Hospital and National Yang Ming University, No. 201, Sec. 2, Shih-Pai Road,
Taipei 112, Taiwan, ROC. Tel.: +886 2 2875 7507; fax: +886 2 2875 6849.
E-mail addresses: krchiou@hotmail.com (K.-R. Chiou),
mjcharng@vghtpe.gov.tw (M.-J. Charng).
http://dx.doi.org/10.1016/j.jjcc.2014.05.010
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsproteins of the cardiac sarcomere [3]. From patients who have been
genotyped successfully, around 70% have been found to have
mutations in the gene encoding b-myosin heavy chain (MYH7) or
myosin-binding protein C (MYBPC3). Troponin T (TNNT2) and
several other genes account for 5% or less of cases. Existing data
have been largely obtained for Caucasian samples. However, no
data have been derived from a systematic screening of HCM from
the Taiwanese, who comprise the major population group in
Taiwan and are the descendants of early settlers from the
southeast coast of China during the past 400 years or more
[4,5]. Although there have been a few systematic surveys of gene-
proven HCM from Chinese [6,7], the relationships need to be
further investigated. Therefore, we investigated the prevalence
and type of mutations among unrelated Taiwanese with symp-
tomatic HCM. In all patients, a systematic screening for mutations
was performed in eight genes that code for the components of the reserved.
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ventricular regulatory light chain 2 (MYL2), myosin ventricular
essential light chain 1 (MYL3), a-tropomyosin (TPM1), and cardiac
a actin (ACTC).
Materials and methods
Subjects
Unrelated symptomatic adult patients were recruited from two
tertiary referral centers (Taipei and Kaohsiung Veterans General
Hospitals, Taiwan). Informed consent was obtained from all the
patients according to institutional guidelines. The condition was
diagnosed following the American College of Cardiology/European
Society of Cardiology (ACC/ESC) criteria, using inclusion criteria of
a left ventricular wall thickness 13 mm on echocardiography
when no other cause explained the hypertrophy [8]. The 12-lead
electrocardiograms obtained at or near the time of initial HCM
diagnosis were assessed. LV hypertrophy by electrocardiographic
criteria was adopted by the Sokolow–Lyon criteria: the sum of S1
wave in V1 and R wave in V5 (or V6) >38 mm [9]. Strain pattern
was characterized by tall lateral precordial voltages in association
with ST–T abnormalities in leads V5 and V6. Prognosis in families
was assessed at the time of genotyping and was based on family
history. A major cardiac event was deﬁned as sudden death, heart
failure death, stroke death, or resuscitated death related to HCM,
each occurring before 60 years of age. Probands with any relative
diagnosed with HCM were considered familial cases, and patients
with proven HCM but without familial history or affected relatives
were considered sporadic cases.
Genetic study
Genomic DNA was isolated from the leukocytes of the
peripheral blood of the patients. Polymerase chain reaction was
used to amplify the exons and ﬂanking intronic bases of the eight
genes, including MYH7 (40 exons), MYBPC3 (35 exons), TNNT2 (17
exons), TNNI3 (8 exons), MYL2 (7 exons), and MYL3 (6 exons). When
no mutation was found, analysis of the TPM1 (nine exons) and ACTC
(six exons) genes was performed. The primers used for the
polymerase chain reaction were designed using reference
sequences deposited in the GenBank database. Information on
the primers and ampliﬁcation conditions can be obtained from the
authors at the correspondence address. Standard DNA sequencing
reactions were performed using the ﬂuorescence-labeled dideoxy
chain termination method with the Big Dye Terminator ABI Prism
Kit and the ABI PRISMTM 3700 DNA Analyzer (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s instructions.
Conﬁrmation of mutation and family genotyping
A variant was considered a mutation in accordance with the
following criteria: (1) presence in tested affected members of the
family of a proband; (2) absence from 200 unrelated chromosomes
of the control subjects; (3) absence from a public database of
polymorphisms, the dbSNP database (http://www.ncbi.nlm.nih.-
gov/projects/SNP/); (4) conservation of the mutated residue
among species and isoforms; and/or (5) the gene has been
reported as an HCM-causing mutation in the literature. Moreover,
the variants were revised to assess their pathogenicity using in
silico tools. The topological placement of the mutations was
localized using the SwissProt database (http://ca.expasy.org/
uniprot/) and the bibliography previously described [10]. The
UniProt database provides generally accepted residue ranges
corresponding with each domain region and specialized subregion.
To predict the pathogenicity of the damaging amino acidsubstitution, four online tools, SIFT (http://sift.jcvi.org/www/
SIFT_seq_submit2.html), Pmut (http://mmb.pcb.ub.es/PMut/),
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and SNAP
(http://www.rostlab.org/services/snap/), were used. A missense
mutation was assumed to be possibly disease-causing if at least
two independent programs indicated a damaging effect. To predict
the altered reading frame in the nonsense mutation, the online
software Open Reading Frame (ORF) Finder from the NCBI (http://
www.ncbi.nlm.nih.gov/projects/gorf/) was used. Family members
of the probands with the identiﬁed mutations were invited to
participate in this investigation, regardless of whether they had
symptoms of the disease.
Statistical analysis
The data for continuous variables have been expressed as mean
value with ranges and compared using the non-parametric
Kruskal–Wallis H test. The data for categorical variables have
been expressed as numbers or percentages and compared using
Fisher’s exact test. Data were collected and analyzed using SPSS
version 14.0 (SPSS Inc., Chicago, IL, USA). A p-value of less than 0.05
was considered statistically signiﬁcant.
Results
Clinical characteristics and genetic results
The clinical characteristics of all patients are summarized in
Table 1. There were no signiﬁcant differences in sex, symptom
severity, LV wall thickness, and presence of LV outﬂow tract (LVOT)
obstruction for the genotype-positive patients and those without
mutations, but genotype-positive patients had an earlier age of
onset at diagnosis and higher incidence of family history of SCD.
The enrolled patients with LVOT >50 mmHg and refractory
medications (44.7%) underwent alcohol septal ablation later.
Overall, 13 mutations in the selected genes were identiﬁed in
13 patients, leading to a genetic diagnosis in 34.2% of the index
patients (Table 2). Five mutations were novel.
The genes most frequently involved in the genotype-positive
patients were MYH7 and MYBPC3, which were mutated in 46.2%
and 30.8% patients, respectively. The other mutated genes (TNNT2,
TNNI3, and MYL3) were involved in 30.8% of cases. The distribution
of the different mutation types was 92.3% missense (n = 12), and
7.7% deletions (n = 1). One patient carried double mutations, with a
mutation in MYH7 R858C and another in TNNT2 R286H. Table 3
shows the echocardiographic and electrocardiographic ﬁndings at
age of diagnosis in index patients carrying mutations.
To determine the pathogenicity of these mutations, we
performed an in silico study and surveyed the family pedigree.
Table 4 shows a suite of different tools. The PolyPhen structure-
based method predicted that all changes were damaging. In
contrast, MYH7 R663H, E1902Q were identiﬁed as a neutral variant
according to SNAP; MYH7 E1902Q, MYBPC3 Q998E and TNNI3
E124Q were identiﬁed as a neutral variant according to Pmut. Five
mutations were novel: one mutation in MYH7, two in MYBPC3, one
in TNNI3, and one in MYL3. All are missense mutations. Analysis
using SIFT, PolyPhen, SNAP, and Pmut showed near consensus for
classifying the ﬁve novel mutations as pathological.
Pedigree and mutations analysis of these ﬁve novel and the double
families
Fig. 1 shows the pedigrees of all the families with novel
mutations and the double mutation. A person with Proband MYH7
R147S experienced chest pain at the age of 48 years. Echocardiog-
raphy showed asymmetric septal hypertrophy (ASH) with mid LV
Table 1
Clinical characteristics of hypertrophic cardiomyopathy patients cohort.
All patients Genotype positive Genotype negative p-value
n = 38 n = 13 n = 25
Male/female 19/19 9/4 10/15 0.087
Age at diagnosis (years)
Mean 60.2  16.0 47.1  14.0 67.2  12.2 0.000
Ranges 18–93 18–72 39–93
Body mass index (kg/m2) 23.8  2.7 23.0  2.0 24.4  3.0 0.166
Syncope 10 (26.3%) 5 (38.5%) 5 (20.0%) 0.220
Cardiac symptoms (NYHA class I–II) 16 (42.1%) 5 (38.5%) 11 (44.0%) 0.743
Cardiac symptoms (NYHA class III–V) 22 (57.9%) 8 (61.5%) 14 (56.0%)
Family history of SCD 7 (18.4%) 5 (38.5%) 2 (8.0%) 0.034
LV septal wall thickness (mm) 19.1  4.3 19.9  6.0 18.7  3.3 0.706
Severe hypertrophy >20 mm 16 (42.1%) 6 (46.2%) 10 (40.0%) 0.399
LVOT pressure (mmHg) 67 (3–133) 52 (3–109) 72 (9–133) 0.128
LVOT >30 mmHg 30 (78.9%) 8 (61.5%) 22 (88.0%) 0.09
LVOT >50 mmHg 28 (73.7%) 7 (53.8%) 21 (84.0%) 0.06
ELVH with strain pattern 26 (68.4%) 8 (61.5%) 18 (72.0%) 0.510
Treatment
Alcohol septal ablation 17 (44.7%) 4 (30.8%) 13 (52.2%) 0.036
PM 3 (7.9%) 3 (23.1%) 0
Medications only 18 (47.4%) 6 (46.2%) 12 (48.0%)
LVOT, left ventricular outﬂow tract; NYHA, New York Heart Association; PM, permanent pacemaker; SCD, sudden cardiac death; LV, left ventricular; ELVH, left ventricular
hypertrophy by electrocardiographic criteria.
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septal ablation and the symptoms were alleviated. Later, he died of
heart failure at the age of 52 years. His son was also diagnosed with
HCM, but his younger daughter and granddaughter were genotype
positive–phenotype negative. The Proband MYBPC3 R597Q was
diagnosed at age 66 years, having experienced chest pain.
Echocardiography showed that he had severe ASH, non-obstruc-
tive type. His eldest son had mild HCM, and his 16-year-old
granddaughter had no disease phenotype. Proband MYBPC3
W1007R was diagnosed at the age of 18 years, after cardiac arrest.
Echocardiography showed severe ASH with an LVOT pressure
gradient of 74 mmHg. His father was said to have experienced SCD.
Proband TNNI3 E124Q was diagnosed at the age of 48 years after
cardiac arrest from which he was successfully resuscitated.
Echocardiography showed LV systolic dysfunction (ejection
fraction 38%) with apical aneurysm. His father and younger sisters
had died suddenly at the ages of 46 and 12 years, respectively. His
daughter had asymptomatic HCM. Proband MYL3 R63C, a 32-year-
old man, experienced dyspnea; electrocardiography exhibited anTable 2
Mutations identiﬁed in MYH7, MYBPC3, TNNT2, TNNI3, and MYL3.
Disease-causing
gene
Mutation site cDNA Amino 
MYH7 Exon 4 c.533C>T p.Arg143Trp 
Exon 4 c.547G>T p.Arg147Ser 
Exon 17 c.2094G>A p.Arg663His 
Exon 22 c. 2678C>T p.Arg858Cys 
Exon 38 c. 5667C>T p.Thr1854Met 
Exon 39 c. 5810G>C p.Glu1902Gln 
MYBPC3 Exon 18 c. 1845G>A p. Arg597Gln 
Exon 27 c. 2919_2920delCT p. Pro955ArgfsX
Exon 28 c. 3047C>G p. Gln998Glu 
Exon 29 c. 3074T>C p. Trp1007Arg 
TNNT2 Exon 16 c. 956G>A p. Arg286His 
TNNI3 Exon 6 c. 513G>C p. Glu124Gln 
MYL3 Exon 3 c. 280T>C p. Arg63Cys 
Bold, mutations not previously described.
S1, globular motor domain, subfragment 1; S2: globular motor domain, subfragm
consecutively (C4, 8); EF hand, a helix-loop-helix structural domain or motif found in
troponin C.intraventricular conduction defect. Echocardiography demon-
strated ASH with an LVOT pressure gradient of 52 mmHg. No
information was available for the cause of his father’s death. The
proband carrying double mutations (MYH7 R858C and TNNT2
R286H) had greater LV hypertrophy than his family members who
carried a single mutation (either MYH7 R858C or TNNT2 R286H)
(Fig. 1f), but none of the family members manifested sudden
death, lethal arrhythmia, LVOT obstruction (pressure gradient
>30 mmHg), or severe heart failure.
Discussion
The study performed sarcomeric gene analysis and cascade
screening for family members. The genetic diagnostic rate was
34.2% in the study cohort. Additionally, ﬁve novel mutations and a
double mutation were identiﬁed. The prevalence of sarcomeric
gene mutations in the study was lower than the reported
prevalence in the US cohort with HCM, the French cohort, and
the Japanese cohort, which were 54.2%, 60.6%, and 43.8%,acid change Mutation
type
Protein location Frequency
(R143W) Missense S1 1
(R147S) Missense S1 1
(R663H) Missense Acting-binding 1
(R858C) Missense S2 1
(T1854M) Missense LMM 1
(E1902Q) Missense LMM 1
(R597Q) Missense C4 1
95 (P955fs) Frameshift Fibronectin type-III 2 1
(Q998E) Missense C8 1
(W1007R) Missense C8 1
(R286H) Missense C-terminal, binding
site of a-TM/cTnC/cTnI
2
(E124Q) Missense cTnC-binding domain 1
(R63C) Missense EF-hand 1 1
ent 2; LMM, light meromyosin; C: immunoglobulin-like domain numbered
 a large family of calcium-binding proteins; a-TM, a-tropomyosin; cTnC, cardiac
Table 3
Echocardiographic and electrocardiographic ﬁndings at age of diagnosis in index patients carrying mutations.
Index LVOT
(mmHg)
MWT
(mm)
IVST
(mm)
PWT
(mm)
MV E/A
velocity
(cm/s)
E/A
ratio
Dec
(ms)
Mean e0
(cm)
Mean
E/e0 ratio
LVEF
(%)
ELVH Q
wave
ST–T Combination
Single mutation
MYH7 R143W H-18 46 18 17 15 82/81 1.02 208 5.9 13.9 72    
MYH7 R147S H-07 109 18 17 9 99/126 0.55 158 6.7 14.8 69 + +  +
MYH7 R663H H-37 86 29 27 14 50/95 0.52 290 3.5 14.3 71 +  + +
MYH7 T1854M H-25 98 23 20 12 108/66 1.63 225 7.1 15.2 61 +  + +
MYH7 E1902Q H-32 3 14 14 10 76/99 0.76 225 6.8 11.1 75 +  + +
MYBPC3 R597Q H-27 18 16 16 12 53/104 0.51 350 4.3 12.3 64 +  + +
MYBPC3 P955fs H-26 56 22 22 15 128/a a 170 8.2 15.6 58 +   +
MYBPC3 Q998E H-06 106 22 21 12 75/118 0.64 380 6.2 12.1 52 +  + +
MYBPC3 W1007R H-35 74 28 27 10 107/51 2.1 200 9.8 10.9 61 +  + +
TNNT2 R286H H-24 12 24 23 15 110/29 3.8 100 10 11 57 +  + +
TNNI3 E124Q H-21 18 14 14 11 35/33 1.06 190 5.2 6.7 38 +  + +
MYL3 R63C H-14 52 16 15 13 82/60 1.37 220 6.2 13.2 58 +   +
Double mutation
MYH7 R858C/
TNNT2 R286H
H-01 15 26 24 10 79/46 1.71 140 5.4 14.6 65 +   +
LVOT, left ventricular outﬂow tract pressure gradient; MWT, maximum wall thickness; IVST, interventricular septum; PWT, posterior wall thickness; MV, mitral valve
inﬂow; Dec, deceleration time; mean e0 , mean of (septal e0 + lateral e0); ELVH, left ventricular hypertrophy by electrocardiographic criteria (Sokolow–Lyon >38 mm); ST–T,
ST segment depression and T wave inversion; Combination: Sokolow–Lyon and/or abnormal Q and/or ST–T.
a No A velocity due to atrial ﬁbrillation.
K.-R. Chiou et al. / Journal of Cardiology 65 (2015) 250–256 253respectively [11–13]. The lower rate in the present study can be
attributed to our enrollment of only symptomatic patients, more
sporadic cases (without family history or affected relatives), and
relatively older age. The failure to identify genetic mutations in
some probands may be due to mutations being present in untested
genes or in the non-coding (intron or promoter) regions of the
genes screened or due to technical limitations of direct DNA
sequencing for large deletion/insertion mutations. In agreement
with the previous studies, the two most common genes were MYH7
and MYBPC3, followed by TNNT2.
In Taiwan, Ko et al. [14,15], using genetic linkage analysis,
reported in 1996 that Taiwanese with HCM might be heterogeneous,
but identiﬁed only one mutation, MYH7 R453C, which was
associated with a malignant clinical course (coexistence of SCD
and end-stage heart failure). Since then, no other sarcomere-related
mutations have been reported in Taiwan. Of the eight previously
described mutations in the study cohort, MYBPC3 P955fs has been
reported frequently in Caucasian and Asian patients [12,16–20]. It
has been conﬁrmed in large families with many affected individuals,
and its penetrance has been found to remain incomplete through the
ﬁfth decade of life. An in vitro functional study reported that the
frameshift truncated mutation causes haploinsufﬁciency and
deranged phosphorylation of the contractile protein [18]. The otherTable 4
Predictions from SIFT, PolyPhen, SNAP, and Pmut for the missense mutations.
Gene Amino acid change SIFT (score) PolyPhe
MYH7 R143W Damaging (0) Probably dam
R147S Damaging (0) Possibly dam
R663H Tolerated (0.1) Possibly dam
R858C Damaging (0) Probably dam
T1854M Damaging (0.02) Probably dam
E1902Q Damaging (0.04) Possibly dam
MYBPC3 R597Q Damaging (0.01) Probably dam
Q998E Damaging (0) Probably dam
W1007R Damaging (0) Probably dam
TNNT2 R286H Damaging (0) Probably dam
TNNI3 E124Q Damaging (0.01) Probably dam
MYL3 R63C Damaging (0) Probably dam
Bold, mutations not previously described.mutations (MYH7 R143W, R663H, R858C, and T1854M; MYBPC3
Q998E; and TNNT2 R286H) were conﬁrmed by either cosegregation
with affected members in the family or were previously recognized
to cause disease in patients with HCM, but the genotype–phenotype
expression varied widely between and within families in clinical
settings [6,7,11,21–25]. To study the functional alterations of the
mutants in the cohort, we used several in silico tools that are
designed to predict the pathogenicity type, showing the bioinfor-
matic prediction software could be an adjuvant tool but that the
prediction must be interpreted carefully.
Among the ﬁve novel mutations in the cohort, the MYH7 R147S
mutation results in an amino acid substitution located in the
globular head of the protein and affects the binding sites for ATP,
actin, and the essential/regular light chain [26,27]. Probands
carrying the mutation MYH7 R147S presented with HCM,
obstructive type, and underwent alcohol septal ablation for relief
of symptoms. Both MYBPC3 R597Q and W1007R mutations result
in changes in the charge of the altered amino acid in the
immunoglobulin-like C4 and C8 domains [28], but the phenotypes
were different in our cohort. The patient with the MYBPC3 R597Q
mutation did not show the phenotype until middle age, whereas
the patient with the MYBPC3 W1007R mutation presented with
severe ASH and sudden death at a young age. The TNNI3 E124Qn (score) SNAP (reliability index) Pmut (reliability index)
aging (0) Non-neutral (2) Pathological (9)
aging (0.942) Non-neutral (1) Pathological (0)
aging (0.844) Neutral (2) Pathological (3)
aging (0.989) Non-neutral (3) Pathological (8)
aging (0.997) Non-neutral (0) Pathological (6)
aging (0.741) Neutral (6) Neutral (1)
aging (0) Non-neutral (3) Pathological (1)
aging (0.992) Non-neutral (1) Neutral (6)
aging (0) Non-neutral (5) Pathological (9)
aging (0) Non-neutral (3) Pathological (6)
aging (0.985) Non-neutral (1) Neutral (4)
aging (1.0) Non-neutral (1) Pathological (8)
Fig. 1. Pedigree and mutation analysis of families with either novel mutations or double mutations. Circles indicate female family members; squares, male family members;
open symbols, unaffected family members; arrows, the proband; symbols with a slash mark, those who have died; question marks, unknown phenotype; and plus signs,
presence of the hypertrophic cardiomyopathy phenotype. The half-ﬁlled symbols indicate heterozygosity. The phenotypes, including age, maximal ventricular wall thickness
by echocardiography, and ECG are presented. ECG(): normal ﬁnding in ECG, ECG(+): presence of Sokolow–Lyon and/or Q wave and/or ST–T. ECG, electrocardiogram.
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the troponin C-binding domains, near the actin-binding domain. In
contrast to previous data, the TNNI3 mutations appeared to cluster
in exons 7 and 8, and not in exon 6 [29]. TNNI3 E124Q family
members showed sudden death, high penetrance, and severe LV
dysfunction; these variable clinical features were similar to TNNI3
Lys 183 deletion mutation reported by Kokado et al. in Japan [30].
End-stage HCM can be seen in around 5% of HCM cases, with highly
unfavorable complications [31,32]. Whether HCM caused by TNNI3
E124Q mutation is malignant prognosis deserves greater investi-
gation. To date, only 12 HCM-causing mutations have been
described in MYL3 [33–35]. The MYL3 R63C mutation is predicted
to be located in the a-helix of the ﬁrst EF-hand domain and to
affect a Ca2+-binding motif. Amino acid alignment across various
species has shown that arginine 63 is highly conserved in MYL3
[35,36]. In the study cohort, the proband MYL3 R63C phenotype
exhibited late onset, dyspnea, an intraventricular conduction
defect, and obstructive HCM.
One proband had two mutations (MYH7 R858C and TNNT2 R286H)
(Fig. 1, H-01). The two missensemutations have been reported before,
but this is the ﬁrst reported patient carrying them simultaneously. In
agreement with the previous study [11], the proband and one family
member carrying the double mutation experienced a dosage effect
associated with severe LV hypertrophy, while others carrying a single
mutation did not. The emerging data suggested that more than one
HCM-associated sarcomere mutation could be associated with
increased disease severity. With continuing improvements, targeted
next-generation sequencing allows simultaneous screening of
multiple genes [37]. It will provide a more comprehensive mutation
screening to identify high-risk patients who would beneﬁt from
earlier treatment and strategies in the future.
The following limitations of the study should be acknowledged.
First, clinical evaluation was not available for some subjects who had
SCD and could not be evaluated before their death. Second,
prospective follow-up studies of clinically unaffected mutation
carriers are required to determine the precise age of disease onset as
well as the true disease penetrance. Third, genes linked to HCM and
with less evidence for pathogenicity, such as those encoding the a-
myosin heavy chain, titin, muscle LIM protein, telethonin, vinculin,
and junctonphilin 2, were not analyzed. Furthermore, non-sarco-
meric protein genes (GLA, GAA, LAMP2, and PRKG2) were not analyzed.
In conclusion, the study identiﬁed 13 HCM pedigrees, including
5 carrying novel mutations and one double mutation from ethnic
Chinese living in Taiwan. The three most commonly mutated genes
were MYH7, MYBPC3, and TNNT2. These results, together with
genetic counseling, could lead to earlier diagnosis and better
management of family members at risk of HCM.
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